Related Experiment Videos
Human cytomegalovirus plasmid-based amplicon vector system for gene therapy
Kutubuddin Mahmood1, Mark N Prichard, Gregory M Duke
1MedImmune Vaccines Inc,, 297 North Bernardo Avenue, Mountain View, CA 94043 USA. spaeter@medimmune.com.
Genetic Vaccines and Therapy
|January 28, 2005
Summary
A novel Human Cytomegalovirus (HCMV) amplicon vector was developed for gene delivery. This system efficiently delivers genes into progenitor cells, offering a new strategy for hematopoietic cell gene therapy.
Area of Science:
- Virology
- Molecular Biology
- Gene Therapy
Background:
- Gene therapy requires efficient and safe delivery vectors.
- Herpes simplex virus (HSV) amplicon vectors are a promising tool for gene delivery.
- Human Cytomegalovirus (HCMV) offers potential for novel vector development.
Purpose of the Study:
- To construct and evaluate a helper-dependent viral vector system derived from HCMV.
- To assess the utility of this HCMV amplicon vector for gene delivery, particularly to hematopoietic progenitor cells.
Main Methods:
- Developed a helper-dependent vector based on the HSV amplicon system.
- Incorporated HCMV-derived elements: oriLyt and the 'a' sequence.
- Evaluated vector replication, packaging, and gene expression in infected cells, including CD34+ cells.
- Assessed serial passage and copy number stability in fibroblasts.
Main Results:
- The HCMV amplicon vector replicated independently and was packaged into infectious virions.
- Successfully delivered and expressed foreign genes in infected cells, including human CD34+ progenitor cells.
- Detected packaged viral genomes after serial passage in fibroblasts, though copy number decreased over time.
Conclusions:
- The constructed HCMV amplicon vector is a viable tool for gene delivery.
- This vector system demonstrates potential for gene delivery to hematopoietic lineage cells.
- It provides an alternative vector strategy for applications in gene therapy targeting blood cells.